Advertisement

Topics

Latest Respiratory NewsRSS

10:44 EST 20th November 2017 | BioPortfolio

Bronchitis Epidemiology Forecast to 2025 [Report Updated: 10102017] Prices from USD $2200

DelveInsight Bronchitis Epidemiology Forecast To 2025 provides an overview of the epidemiology trends of Bronchitis in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Bronchitis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease...

Chronic Obstructive Pulmonary Disease COPD Epidemiology Forecast to 2025 [Report Updated: 10112017] Prices from USD $2200

DelveInsight Chronic Obstructive Pulmonary Disease COPD Epidemiology Forecast To 2025 provides an overview of the epidemiology trends of Chronic Obstructive Pulmonary Disease COPD in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Chronic Obstructive Pulmonary Disease COPD prevalent or incident cases segmente...

FDA Nod For Label Expansion Of Sutent, Egalet Flies, Double Blessing For Roche

Today's Daily Dose brings you news about Aerie's progress in phase II trial of glaucoma drug in Japan; phase III results of Egalet's pain pill; FDA approval of GlaxoSmithKline's COPD drug; expanded labeling for Pfizer's kidney cancer drug Sutent and Roche's double blessing on Thursday.

Copley Scientific Introduces New, Upgraded Breath Simulators for Inhaled Product Testing

The advanced breath simulators, the BRS 2100 and BRS 3100, are designed for orally inhaled product (OIP) development and testing

Propeller Health, Express Scripts Partner to Offer Innovative Digital Respiratory Care

Propeller Health and Express Scripts has announced a strategic partnership to provide Propeller’s FDA-cleared digital solution to Express Scripts members using inhaler sensors and a mobile app to manage asthma or COPD. This collaboration represents the largest respiratory digital health deployment with a pharmacy benefit manager to date. Propeller’s digital sensors enable remote monito...

Europe approves GlaxoSmithKline's new triple lung drug

Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease , putting GSK ahead of rivals such as AstraZeneca and Novartis.

Chronic Obstructive Pulmonary Disease COPD Market Insights, Epidemiology and Market Forecast 2025 [Report Updated: 10102017] Prices from USD $4600

DelveInsight's Chronic Obstructive Pulmonary Disease COPD Market Insights, Epidemiology and Market Forecast Market Insights, Epidemiology and Market Forecast 2025 report provides an overview of the disease and in depth research related to Chronic Obstructive Pulmonary Disease COPD Market Insights, Epidemiology and Market Forecast for the 7MM United States, Germany, France, Italy, Spain and UK ...

Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’) as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are n...

AstraZeneca's Fasenra Approved By FDA For Severe Eosinophilic Asthma

NewsFasenra distinctively targets and rapidly depletes eosinophils and is the first respiratory biologic with an 8-week maintenance dosing schedule.

Bronchitis Market Insights, Epidemiology and Market Forecast 2025 [Report Updated: 10102017] Prices from USD $4600

DelveInsight's Bronchitis Market Insights, Epidemiology and Market Forecast Market Insights, Epidemiology and Market Forecast 2025 report provides an overview of the disease and in depth research related to Bronchitis Market Insights, Epidemiology and Market Forecast for the 7MM United States, Germany, France, Italy, Spain and UK for the study period undertaken from 20152025.This report provid...

Global and Asia Nebulizers Market Status and Future Forecast 20132023 [Report Updated: 08112017] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPart 3:Asia Market by company, Type, Application RegionPart 410:Key Regions of Asia Market by Type, ApplicationPart 11:Company information, Sales, Cost, Margin etc.Part 12:ConclusionMarket Segment as fo...

Leicester and Nottingham Scientists Discover New Gene Associated with Debilitating Lung Disease

Finding of lung fibrosis gene highlights a potential new avenue for treatment Health scientists at the University of Leicester and University of Nottingham have heralded the discovery of a gene associated with lung fibrosis as ‘a potential new avenue of treatment for further research into this terrible disease.’ The breakthrough is announced in a paper published in The Lancet Respirato...

Chronic Obstructive Pulmonary Disease COPD Epidemiology Forecast to 2025 [Report Updated: 10102017] Prices from USD $2750

DelveInsight Chronic Obstructive Pulmonary Disease COPD Epidemiology Forecast To 2025 provides an overview of the epidemiology trends of Chronic Obstructive Pulmonary Disease COPD in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Chronic Obstructive Pulmonary Disease COPD prevalent or incident cases segmente...

Theravance submits U.S. marketing application for COPD med revefenacin

Theravance Biopharma and development/commercialization partner Mylan N.V. announce the filing of a New Drug Application in the U.S. seeking approval for revefenacin for the once-daily treatment of chronic obstructive pulmonary disease . The companies are collaborating on the development of the long-acting nebulized bronchodilator.

Chronic Obstructive Pulmonary Disease COPD Market Insights, Epidemiology and Market Forecast 2025 [Report Updated: 10102017] Prices from USD $5750

DelveInsight's Chronic Obstructive Pulmonary Disease COPD Market Insights, Epidemiology and Market Forecast Market Insights, Epidemiology and Market Forecast 2025 report provides an overview of the disease and in depth research related to Chronic Obstructive Pulmonary Disease COPD Market Insights, Epidemiology and Market Forecast for the 7MM United States, Germany, France, Italy, Spain and UK ...

Chiesi Farmaceutici SpA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25102017] Prices from USD $250

SummaryChiesi Farmaceutici SpA Chiesi researches, develops, produces and commercializes novel medicines with focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease COPD, asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea o...

Respiratory syncytial virus RSV Epidemiology Forecast to 2025 [Report Updated: 10102017] Prices from USD $2750

DelveInsight Respiratory syncytial virus RSV Epidemiology Forecast To 2025 provides an overview of the epidemiology trends of Respiratory syncytial virus RSV in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Respiratory syncytial virus RSV prevalent or incident cases segmented by age, sex and subpopulations....

ED Claims Involving High-dose Analgesics Carry Jury Appeal

Recent successful ED claims involving high-dose analgesics focused on failure to monitor patients and improper discharge. The malpractice lawsuits alleged that a patient was seriously injured because he or she was allowed to leave the ED while sedated, a patient went into respiratory arrest because of unsafe discharge, and the ED failed to monitor a patient adequately, resulting in the patient’s...

Synairgen Plc SNG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25102017] Prices from USD $250

SummarySynairgen plc Synairgen is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease COPD. Its pipeline portfolio includes inhaled interferon beta IFN/SNG001 for asthma in Phase II trial; and IFN SNG001 for COPD in Phase I trial. The company develops its drugs b...

Art of Dentistry Raises Awareness of the Oral Health-Diabetes Link, Offers Laser Treatment for Gum Disease in San Diego, CA

Art of Dentistry supports National Diabetes Month by raising awareness of the link between diabetes and untreated oral health issues including gum disease. Drs. Lawrence Addleson, R. Douglas Campbell and David Landau now accept new patients with bleeding gums and other symptoms of gum disease in San Diego, CA, for consultations without a referral. San Diego, CA (PRWEB) November 09, 2017 The trust...

Chronic Obstructive Pulmonary Disease COPD Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $2000

Chronic Obstructive Pulmonary Disease COPD Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease COPD Pipeline Review, H2 2017, provides an overview of the Chronic Obstructive Pulmonary Disease COPD Respiratory pipeline landscape.Chronic obstructive pulmonary disease COPD is a group of lung disease...

Medical VideoscopesGlobal Market Status and Trend Report 20132023 [Report Updated: 23102017] Prices from USD $3480

Report SummarySleep and Respiratory Care DevicesUnited States Market Status and Trend Report 20132023 offers a comprehensive analysis on Sleep and Respiratory Care Devices industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and informat...

Bronchiectasis Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $2000

Bronchiectasis Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis Pipeline Review, H2 2017, provides an overview of the Bronchiectasis Respiratory pipeline landscape.Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up i...

Significant cost reduction in COPD care with simple, drug-free device

PLATTSBURGH, NY -- (Marketwired) -- 11/08/17 -- The Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device (Monaghan Medical Corporation) is a cost-effective treatment option in the management of COPD exacerbations, according to a study published October 20th in the International Journal of COPD.1 This study, which used data from the published literature and national fee schedules to m...

Aradigm to Host Key Opinion Leader Meeting and Webcast on November 9 in New York City

Aradigm Corporation (Nasdaq: ARDM) (the “Company”) announced today that it will host a Key Opinion Leader (KOL) Breakfast on the topic of Non-Cystic Fibrosis Bronchiectasis (NCFBE) on Thursday, November 9, 2017 from 8:00-9:30 am Eastern Time in New York, NY. The breakfast meeting will feature a presentation by Prof. James Chalmers (University of Dundee...

Quick Search
Advertisement
 

review and buy Respiratory market research data and corporate reports here